Article ; Online: Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases.
Nutrition (Burbank, Los Angeles County, Calif.)
2020 Volume 83, Page(s) 111089
Abstract: The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no ... ...
| Abstract | The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this viral disease, but the use of masks and social distancing can limit the spread. Boosting immunity has been a simple way to resist viral infection and limit fatalities. In this context, the use of nutraceuticals appears to be a potential panacea. The ability of algae-based nutraceuticals, mainly Spirulina, to boost immunity against viral diseases has already been reported clinically. Spirulina-based nutraceuticals boost the adaptive and innate immunity, and bioactive compounds, such as angiotensin-converting enzyme (ACE) inhibitor peptides, phycobiliproteins, sulfated polysaccharides, and calcium-Spirulan, can serve as antiviral agents. The presence of these molecules indicates its potential role in resisting infection and COVID-19 disease progression. This review focuses on the potential role of algal nutraceuticals as immune boosters to combat the human coronavirus and other viral diseases. The potential use of Spirulina-based nutraceuticals for combating COVID-19, its mechanism, and future directions have also been discussed. |
|---|---|
| MeSH term(s) | Biological Products/pharmacology ; Biological Products/therapeutic use ; COVID-19/drug therapy ; Dietary Supplements ; Humans ; Immunologic Factors/pharmacology ; Immunologic Factors/therapeutic use ; SARS-CoV-2/drug effects ; Spirulina/chemistry |
| Chemical Substances | Biological Products ; Immunologic Factors |
| Language | English |
| Publishing date | 2020-11-21 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
| ZDB-ID | 639259-3 |
| ISSN | 1873-1244 ; 0899-9007 |
| ISSN (online) | 1873-1244 |
| ISSN | 0899-9007 |
| DOI | 10.1016/j.nut.2020.111089 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2290: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.